z-logo
open-access-imgOpen Access
IN-VITRO CYTOTOXICITY AND ANTIOXIDANT EVALUATION OF 7-AMINO-2-STYRYLCHROMONE DERIVATIVES
Author(s) -
Lalitha Simon
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i11.20587
Subject(s) - dpph , antioxidant , cytotoxicity , chemistry , amino acid , bromide , nitric oxide , ic50 , in vitro , stereochemistry , biochemistry , organic chemistry
  Objective: The objective of this study was to synthesize 7-amino-2-styrylchromone derivatives and evaluate their in vitro cytotoxic and antioxidant potential.Methods: 7-amino-2-styrylchromones were synthesized from 7-amino-2-methylchromone by condensing it with various substituted aromatic aldehydes. The cytotoxicity of the synthesized molecules was assessed against two cell lines, MCF-7 and HCT-116 by 3-(4,5-dimethyl thiazol-2-yl)-2,5- diphenyl tetrazolium bromide assay. Cell cycle analysis of the most potent molecule ASC-7 was carried out. The antioxidant studies were conducted by 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide methods.Result: (E)-7-amino-2-(3,4-methylenedioxystyryl)-4H-chromen-4-one (ASC-7) with inhibitory concentration 50% (IC50) 56.0 μM was found to be the most potent molecule against MCF-7. ASC-7 induced G0/G1 phase arrest of MCF-7. Furthermore, (E)-7-amino-2-(3,4-methylenedioxystyryl)- 4H-chromen-4-one(ASC-7) showed good DPPH scavenging activity (IC50 54.6 μM). However, none of the tested compounds exhibited nitric oxide scavenging property.Conclusion: This study reports the synthesis of 7-amino-2-styrylchromones. Some of the synthesized compounds showed moderate cytotoxicity against the tested cell lines MCF-7 and HCT-116. (E)-7-amino-2-(3,4-methylenedioxystyryl)-4H-chromen-4-one (ASC-7) was found to be the best cytotoxic and antioxidant agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here